Literature DB >> 24398459

Use of cassette dosing approach to examine the effects of P-glycoprotein on the brain and cerebrospinal fluid concentrations in wild-type and P-glycoprotein knockout rats.

Xingrong Liu1, Jonathan Cheong, Xiao Ding, Gauri Deshmukh.   

Abstract

The study objectives were 1) to test the hypothesis that the lack of P-glycoprotein (P-gp) and the inhibition of breast cancer resistance protein (Bcrp) at the blood-brain barrier after cassette dosing of potent P-gp and Bcrp inhibitors were due to low plasma concentrations of those inhibitors and 2) to examine the effects of P-gp on the unbound brain (C(u,brain)) and cerebrospinal fluid (CSF) concentrations (C(u,CSF)) of P-gp substrates in rats. In vitro inhibition of 11 compounds (amprenavir, citalopram, digoxin, elacridar, imatinib, Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1',2':1,6]pyrido[3,4-b]indole-3-propanoic acid 1,1-dimethylethyl ester], loperamide, prazosin, quinidine, sulfasalazine, and verapamil) on P-gp and Bcrp was examined in P-gp- and Bcrp-expressing Madin-Darby canine kidney cells, respectively. An in vivo study was conducted in wild-type and Mdr1a(-/-) rats after subcutaneous cassette dosing of the 11 compounds at 1-3 mg/kg, and the brain, CSF, and plasma concentrations of these compounds were determined. At the maximal unbound concentrations observed in rats at 1-3 mg/kg, P-gp and Bcrp were not inhibited by a cassette of the 11 compounds. For non-P-gp/Bcrp substrates, similar C(u,brain), C(u,CSF), and unbound plasma concentrations (C(u,plasma)) were observed in wild-type and P-gp knockout rats. For P-gp/Bcrp substrates, C(u,brain) ≤ C(u,CSF) ≤ C(u,plasma) in wild-type rats, but C(u,brain) and C(u,CSF) increased in the P-gp knockout rats and were within 3-fold of C(u,plasma) for six of the seven P-gp substrates. These results indicate that P-gp and Bcrp inhibition at the blood-brain barrier is unlikely in cassette dosing and also suggest that P-gp and Bcrp activity at the blood-CSF barrier is functionally not important in determination of the CSF concentration for their substrates.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24398459     DOI: 10.1124/dmd.113.055590

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  7 in total

Review 1.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

Review 2.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

3.  The Inhibitor Ko143 Is Not Specific for ABCG2.

Authors:  Lora D Weidner; Sami S Zoghbi; Shuiyu Lu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Jan Mulder; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  J Pharmacol Exp Ther       Date:  2015-07-06       Impact factor: 4.030

Review 4.  Rat models of human diseases and related phenotypes: a systematic inventory of the causative genes.

Authors:  Claude Szpirer
Journal:  J Biomed Sci       Date:  2020-08-02       Impact factor: 8.410

5.  Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.

Authors:  Severin Mairinger; Viktoria Zoufal; Thomas Wanek; Alexander Traxl; Thomas Filip; Michael Sauberer; Johann Stanek; Claudia Kuntner; Jens Pahnke; Markus Müller; Oliver Langer
Journal:  Eur J Pharm Sci       Date:  2018-01-31       Impact factor: 4.384

6.  Optimization of dose and route of administration of the P-glycoprotein inhibitor, valspodar (PSC-833) and the P-glycoprotein and breast cancer resistance protein dual-inhibitor, elacridar (GF120918) as dual infusion in rats.

Authors:  Christopher Rowbottom; Alicia Pietrasiewicz; Taras Tuczewycz; Richard Grater; Daniel Qiu; Sudarshan Kapadnis; Patrick Trapa
Journal:  Pharmacol Res Perspect       Date:  2021-04

7.  Determinants of drug entry into the developing brain.

Authors:  Liam Koehn; Mark Habgood; Yifan Huang; Katarzyna Dziegielewska; Norman Saunders
Journal:  F1000Res       Date:  2019-08-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.